Today: November 13, 2018, 5:49 pm
  
Business

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

PR-Inside.com: 2018-09-14 09:48:05

Company announcement - No. 22 / 2018

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Copenhagen, September 14, 2018 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 7,500 divided into 7,500 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs. Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre specified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand's warrant programs, see the company's Articles of Association, which are available on the website: www.zealandpharma.com.

The exercise price was DKK 101.20 per share and the total proceeds to Zealand from the capital increase amount to DKK 759,000.00.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand has only one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 30,758,827 divided into 30,758,827 shares with a nominal value of DKK 1 each.

The amendment to Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand's current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand's portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

22-18_0914_announcement_capital increase_final



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via Globenewswire




# 637 Words
Related Articles
More From The Author
Quantenna and SoftAtHome Deliver Turnkey 802.11ax Solutions [..]
AMSTERDAM, The Netherlands, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ: QTNA), the innovator and [..]
Quantenna Powers Up Orange Poland’s Smart Wi-Fi [..]
AMSTERDAM, The Netherlands, Sept. 14, 2018 (GLOBE NEWSWIRE) -- IBC 2018 -- Quantenna Communications, Inc. (NASDAQ: QTNA), the [..]
Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI [..]
Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will [..]
Asia Lifestyle Expo 2019 Launches in Bangkok
Taking its lead from the One Belt One Road initiative, Asia Lifestyle Expo 2019 will arrive in Bangkok next year. This [..]
Primerica Canada CEO Comments on Remarks Made [..]
Earlier today, the Honourable Vic Fedeli, Ontario Minister of Finance, issued a statement regarding the Canadian Securities Administrators’ [..]
 
More From Business
NJAWBO Annual Holiday Dinner & Expo for [..]
The New Jersey Association of Women Business Owners (NJAWBO) Annual Statewide Holiday Dinner and Expo will take place on November [..]
Have the coziest living room with Marble [..]
UK – 12th November 2018 – Often times we want our apartmens and houses to be cozier, and thus, more [..]
Huge Success for Iberia Consulting´s B2B Meetings [..]
The annual Eurasia Packaging Fair is a 4-day event that started on the 31st of October until the 3rd of [..]
Revelation Creative Certified by the Women’s Business [..]
Revelation Creative, a business specializing in digital marketing, web and print design, and branding, is proud to announce national [..]
Why Unified Acquires UK Payment Processor, Verified [..]
Why Unified, the Tampa, Florida sales and marketing platform has announced a pending acquisition of Verified Payments, a UK [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.